Skip to content
Advertisement

FILE - This Oct. 14, 2015 file photo shows the Food & Drug Administration campus in Silver Spring, Md. On Friday, March 8, 2019, the FDA approved Roche’s Tecentriq, the first cancer immunotherapy for treating an aggressive type of breast cancer. (AP Photo/Andrew Harnik, File)

FILE - This Oct. 14, 2015 file photo shows the Food & Drug Administration campus in Silver Spring, Md. On Friday, March 8, 2019, the FDA approved Roche’s Tecentriq, the first cancer immunotherapy for treating an aggressive type of breast cancer. (AP Photo/Andrew Harnik, File)

Featured Photo Galleries